pioglitazone has been researched along with Osteogenic Sarcoma in 3 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we report a treatment strategy for osteosarcoma using hydrogel-microspheres (Gel-Mps) complex mainly composed of collagenase (Col) and PLGA microspheres (Mps) carrying Pioglitazone (Pio) and Doxorubicin (Dox)." | 8.31 | Sequentially degradable hydrogel-microsphere loaded with doxorubicin and pioglitazone synergistically inhibits cancer stemness of osteosarcoma. ( Cao, J; Du, X; Ke, X; Li, C; Wei, L; Zhang, X; Zhao, H; Zhu, C, 2023) |
| "Osteosarcoma has been reported with treatment failure in up to 40% of cases." | 5.62 | Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft. ( Gopisetty, G; Jayavelu, S; Natarajan, A; Rajkumar, T; Ramachandran, B; Sundersingh, S, 2021) |
| " Here, we report a treatment strategy for osteosarcoma using hydrogel-microspheres (Gel-Mps) complex mainly composed of collagenase (Col) and PLGA microspheres (Mps) carrying Pioglitazone (Pio) and Doxorubicin (Dox)." | 4.31 | Sequentially degradable hydrogel-microsphere loaded with doxorubicin and pioglitazone synergistically inhibits cancer stemness of osteosarcoma. ( Cao, J; Du, X; Ke, X; Li, C; Wei, L; Zhang, X; Zhao, H; Zhu, C, 2023) |
| "Osteosarcoma has been reported with treatment failure in up to 40% of cases." | 1.62 | Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft. ( Gopisetty, G; Jayavelu, S; Natarajan, A; Rajkumar, T; Ramachandran, B; Sundersingh, S, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, J | 1 |
| Du, X | 1 |
| Zhao, H | 1 |
| Zhu, C | 1 |
| Li, C | 1 |
| Zhang, X | 1 |
| Wei, L | 1 |
| Ke, X | 1 |
| Higuchi, T | 1 |
| Sugisawa, N | 1 |
| Miyake, K | 1 |
| Oshiro, H | 1 |
| Yamamoto, N | 1 |
| Hayashi, K | 1 |
| Kimura, H | 1 |
| Miwa, S | 1 |
| Igarashi, K | 1 |
| Kline, Z | 1 |
| Bouvet, M | 1 |
| Singh, SR | 1 |
| Tsuchiya, H | 1 |
| Hoffman, RM | 1 |
| Natarajan, A | 1 |
| Ramachandran, B | 1 |
| Gopisetty, G | 1 |
| Jayavelu, S | 1 |
| Sundersingh, S | 1 |
| Rajkumar, T | 1 |
3 other studies available for pioglitazone and Osteogenic Sarcoma
| Article | Year |
|---|---|
Sequentially degradable hydrogel-microsphere loaded with doxorubicin and pioglitazone synergistically inhibits cancer stemness of osteosarcoma.
Topics: Bone Neoplasms; Cell Line, Tumor; Doxorubicin; Humans; Hydrogels; Microspheres; Neoplasm Recurrence, | 2023 |
Pioglitazone, an agonist of PPARĪ³, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.
Topics: Adolescent; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Body Weight; Cell Line | 2019 |
Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft.
Topics: Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone | 2021 |